MRK’s Tredaptive failure will make the EMA demand more clinical data for all chronic-use drugs, opines John LaMattina: http://www.forbes.com/sites/johnlamattina/2013/01/02/will-mercks-failure-with-tredaptive-impact-how-drugs-are-approved-in-europe/ I think he’s right.